New pill combo could delay advanced breast cancer progression
NCT ID NCT07371910
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of two targeted pills (fluorizoparib and apatinib) works better than standard chemotherapy for people with a specific genetic type of advanced breast cancer (HRD-positive, HER2-negative). About 200 participants will be randomly assigned to either the pill combo or continued chemo. The goal is to see if the pills can delay cancer growth with fewer side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Could a personal coach at home boost energy for cancer patients?
- Can an immune booster help chemotherapy fight metastatic breast cancer?
- Can a Four-Drug cocktail tame a tough breast cancer?
- Can a new drug outsmart resistant breast cancer?